ATLANTA – Health care technology company Jvion is collaborating with the COPD Foundation, the Geisinger health system and health care company GSK to leverage cognitive machine technology and data for patients with chronic obstructive pulmonary disease.
The goal of the collaboration is to use Jvion’s Cognitive Clinical Success Machine to identify COPD patients who are currently under the care of Geisinger and who are at risk of hospitalization and most likely to benefit from new medications.
“By combining COPD disease expertise with the exceptional patient care delivered by Geisinger and Jvion’s leading Cognitive Clinical Success Machine, we are positioned to help patients across the nation,” said Craig Kephart, CEO of the COPD Foundation, in a statement. “This work is intended to demonstrate the power of leading edge, cognitive technology and patient care management to halt instances of rising risk and improve COPD patient lives.”
The Cognitive Clinical Success Machine is an advanced artificial intelligence solution built using Eigenspace—an approach that helps solve complex challenges such as quantum mechanics, search and consumer behavior, facial recognition and patient deterioration. It enables a comprehensive patient view that is amplified beyond the risk of an event to the clinical actions that will improve outcomes and drive patient engagement.
The project, funded by GSK, is divided into two phases. Phase one will target COPD patients who have had an inpatient stay and who are at risk of a readmission within 30 days of their initial discharge; phase two will focus on identifying COPD patients at-risk of an avoidable hospitalization.
“This work has the potential to revolutionize how we support COPD patients both inside and outside of the hospital,” said Dr. Paul Simonelli, director of thoracic medicine at Geisinger, in a statement. “We hope to demonstrate how innovation can improve quality, while lowering costs for vulnerable patient populations.”